Brett Dovman

Associate
Full contact info

Experience

TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation

August 16, 2023

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Read more

Related contacts

Matt Browne
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Rupa Briggs
Partner, New York
Rajdeep Roger Bains
Associate, San Diego
Alexander Gefter
Associate, Los Angeles Santa Monica
Brett Dovman
Associate, San Diego
Jayden Martinez
Associate, Colorado
Pitrina Gilger
Associate, San Diego
Carlos Ramirez
Partner, San Diego
Mischi a Marca
Partner, San Francisco
Matthew S. Scarano
Associate, San Diego
Margaret Barreto
Associate, San Francisco
Jeffrey J. Tolin
Partner, New York
Patrick Sharma
Associate, Los Angeles Santa Monica
Alessandra Murata
Partner, Palo Alto
Ryan Montgomery
Special Counsel, Boston
Zimu Yang
Associate, Washington DC
Sharon Connaughton
Special Counsel, Washington DC
Natasha Leskovsek
Of Counsel, Washington DC
Natasha Leskovsek
Of Counsel, Washington DC
Phil Mitchell
Partner, New York
Francis Wheeler
Partner, Colorado
Howard Morse
Partner, Washington DC
Madison (JJ) Meng
Associate, San Francisco
Sarah Sellers
Partner, New York
Lei Shen
Partner, Chicago
Kristin R. Marshall
Associate, Washington DC
Vince Sampson
Special Counsel, Washington DC
Ehijele Olumese
Associate, Los Angeles Downtown
Darren DeStefano
Partner, Reston
Darren DeStefano
Partner, Reston
Jennifer Shanley
Special Counsel, New York
Charity Williams
Partner, San Diego
Grady Chang
Associate, Los Angeles Santa Monica
Ross Eberly
Partner, Los Angeles Santa Monica
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries

Ambrx Biopharma – $126 Million IPO

June 18, 2021

Cooley advised Ambrx Biopharma on its $126 million initial public offering of 7,000,000 American depositary shares, each representing seven ordinary shares. Ambrx Biopharma, whose securities now trade on the New York Stock Exchange under the symbol AMAM, is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop engineered precision biologics. Partners Charlie Kim, Patrick Loofbourrow, Sean Clayton and Will Cai led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Will Cai
Partner, Hong Kong
Alexa M. Smith (Ekman)
Associate, San Diego
Brett Dovman
Associate, San Diego

Related Practices & Industries

MannKind – $200 Million Convertible Notes Offering

March 2, 2021

Cooley advised MannKind on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. MannKind, whose securities trade on the Nasdaq Global Market under the symbol MNKD, focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Partners Sean Clayton, Mischi a Marca and Jason Savich led the Cooley team.

Related contacts

Mischi a Marca
Partner, San Francisco
Jason Savich
Partner, San Francisco
Carlos Ramirez
Partner, San Diego
Brett Dovman
Associate, San Diego
Molly Niffenegger
Associate, San Francisco

Related Practices & Industries

Silverback Therapeutics– $278 Million IPO

December 3, 2020

Cooley advised Silverback Therapeutics on its $277.7 million initial public offering of 13,225,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Silverback Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol SBTX, is a biopharmaceutical company that develops proprietary ImmunoTAC therapies targeting previously inaccessible disease pathways. Partners Ken Rollins and Charlie Kim led the Cooley team.

Related contacts

Ken Rollins
Partner in Charge – San Diego, San Diego
Charlie Kim
Partner, San Diego
Brett Dovman
Associate, San Diego

Related Practices & Industries

Kronos Bio – $288 million IPO

October 8, 2020

Cooley advised Kronos Bio on its $287.5 million initial public offering of 15,131,579 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Kronos Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol KRON, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Partners Charles Bair, Charlie Kim and Chad Mills led the Cooley team.

Related contacts

Charles Bair
Partner, San Diego
Chadwick Mills
Partner, San Francisco
Asa Henin
Special Counsel, San Diego
Alexa M. Smith (Ekman)
Associate, San Diego
Brett Dovman
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries

View more